CORCEPT THERAPEUTICS INC (CORT) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-30

Key Insights

Corcept disclosed Q1 2026 financial results and corporate update via press release on April 30, 2026, indicating the company is actively communicating operational performance to the market.
The filing is a routine quarterly earnings announcement (Items 2.02 and 7.01) with the actual financial details contained in the attached press release (Exhibit 99.1), which is not incorporated into SEC filings per the standard disclosure language.
The 8-K was signed by CFO Atabak Mokari, suggesting normal financial reporting procedures and stability in the company's financial leadership as of the filing date.

Want the newest filings?

This analysis covers the filing from 2026-04-30. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-02-24

Corcept Therapeutics reported its financial results for Q4 2025, providing investors with a corporate update.
The company's press release indicates strong financial performance, potentially signaling continued growth and operational success.
Investors should monitor the company's ongoing business developments and assess the potential impact on future financial and operational results.

Filed: 2026-02-19

Corcept Therapeutics has prevailed in a patent dispute, as the U.S. Court of Appeals ruled that Teva Pharmaceuticals' generic version of Korlym does not infringe on two of Corcept's key patents.
This decision allows Teva to continue marketing its generic version of Korlym, which could potentially impact Corcept's future revenue and market share for the drug.
Investors should closely monitor the ongoing patent landscape and any potential impact on Corcept's competitive positioning and financial performance.

Filed: 2026-01-22

Corcept Therapeutics announced that its pivotal Phase 3 trial of relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer met its overall survival primary endpoint, a significant clinical milestone.
The positive results from the ROSELLA trial could potentially lead to regulatory approval and commercialization of Corcept's relacorilant combination therapy, expanding the company's product portfolio and revenue opportunities.
Investors should closely monitor future updates on the regulatory progress and commercial launch plans for Corcept's new ovarian cancer treatment, as it could have a substantial impact on the company's financial performance.

Filed: 2025-12-31

The FDA has issued a Complete Response Letter regarding Corcept's New Drug Application for relacorilant, a potential treatment for hypertension secondary to hypercortisolism.
This delay in the FDA approval process could impact Corcept's near-term revenue growth and pipeline development timelines.
Investors should closely monitor Corcept's response to the FDA's Complete Response Letter and any updates on the relacorilant development program.

Other reports for CORCEPT THERAPEUTICS INC

Insider Trading Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.